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T

he sorting of signaling receptors to lysosomes is an
essential regulatory process in mammalian cells.
During degradation, receptors are modiﬁed with
ubiquitin and sorted by endosomal sorting complex required for transport (ESCRT)–0, –I, –II, and –III complexes
into intraluminal vesicles (ILVs) of multivesicular bodies
(MVBs). However, it remains unclear whether a single universal mechanism mediates MVB sorting of all receptors.
We previously showed that protease-activated receptor 1
(PAR1), a G protein–coupled receptor (GPCR) for thrombin, is internalized after activation and sorted to lysosomes
independent of ubiquitination and the ubiquitin-binding

ESCRT components hepatocyte growth factor–regulated
tyrosine kinase substrate and Tsg101. In this paper,
we report that PAR1 sorted to ILVs of MVBs through an
ESCRT-III–dependent pathway independent of ubiquitination. We further demonstrate that ALIX, a charged MVB
protein 4–ESCRT-III interacting protein, bound to a YPX3L
motif of PAR1 via its central V domain to mediate lysosomal
degradation. This study reveals a novel MVB/lysosomal
sorting pathway for signaling receptors that bypasses
the requirement for ubiquitination and ubiquitin-binding
ESCRTs and may be applicable to a subset of GPCRs containing YPXnL motifs.

Introduction
G protein–coupled receptors (GPCRs) are the largest family of
signaling receptors expressed in mammalian cells and mediate
vast physiological responses. The temporal and spatial fidelity
of GPCR signaling is critical for appropriate cellular responses.
Moreover, dysregulated GPCR signaling has been implicated in
numerous human diseases including neurodegeneration and
cancer progression (Hanyaloglu and von Zastrow, 2008; Marchese
et al., 2008). In addition to desensitization, GPCR trafficking is
important for the precise regulation of signaling responses. This
is particularly true for protease-activated receptor 1 (PAR1), a
GPCR for thrombin (Coughlin, 2000; Arora et al., 2007). Thrombin cleaves the N terminus of PAR1, unmasking a new N-terminal
domain, which functions as a tethered ligand that activates
the receptor through intramolecular binding (Vu et al., 1991).
M.R. Dores and B. Chen contributed equally to this paper.

Once activated, PAR1 is internalized and sorted directly to lysosomes and degraded, a process important for termination
of G protein signaling (Trejo et al., 1998; Booden et al., 2004).
The mechanism by which activated PAR1 is trafficked to lysosomes is not known.
The sorting of transmembrane proteins such as EGF receptor (EGFR) from the plasma membrane to lysosomes has
been extensively studied and is mediated by the endosomal
sorting complex required for transport (ESCRT). The ESCRT
machinery is comprised of distinct complexes that function coordinately to sort ubiquitinated receptors to intraluminal vesicles
(ILVs) of multivesicular bodies (MVBs; Hurley and Hanson,
2010). Hepatocyte growth factor–regulated tyrosine kinase substrate (HRS), a component of ESCRT-0, recruits ubiquitinated
receptors and Tsg101, a ubiquitin-binding subunit of ESCRT-I
(Lu et al., 2003). ESCRT-I and -II function in receptor sorting to

Downloaded from jcb.rupress.org on July 31, 2012

THE JOURNAL OF CELL BIOLOGY

3

Correspondence to JoAnn Trejo: joanntrejo@ucsd.edu
Abbreviations used in this paper: BCA, bicinchoninic acid; CHMP, charged
MVB protein; DOR, D-opioid receptor; EGFR, EGF receptor; ESCRT, endosomal
sorting complex required for transport; GPCR, G protein–coupled receptor; HRS,
hepatocyte growth factor–regulated tyrosine kinase substrate; ILV, intraluminal
vesicle; MVB, multivesicular body; WT, wild type.

© 2012 Dores et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the ﬁrst six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
Supplemental Material can be found at:
http://jcb.rupress.org/content/suppl/2012/04/26/jcb.201110031.DC1.html

The Rockefeller University Press $30.00
J. Cell Biol. Vol. 197 No. 3 407–419
www.jcb.org/cgi/doi/10.1083/jcb.201110031

JCB

407

Published April 30, 2012

Results
Activated PAR1 sorts to ILVs of MVBs
independent of ubiquitination

Activated PAR1 WT is internalized, sorted efficiently to lysosomes, and rapidly degraded with a half-life of 30 min (Trejo
and Coughlin, 1999). In previous work, we showed that a PAR1
lysine-less 0K mutant defective in ubiquitination is degraded
comparably with WT receptor after activation (Wolfe et al.,
2007), suggesting that PAR1 degradation occurs independent
of ubiquitination. To investigate the mechanism of ubiquitinindependent degradation of PAR1, we first determined whether
agonist promoted lysosomal sorting of the PAR1 0K mutant
408
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Figure 1. PAR1 is sorted to MVBs independent of ubiquitination. (A) HeLa
cells expressing FLAG-PAR1 WT or 0K mutant were pretreated with 0.2 mM
leupeptin. Cells were then incubated without (Control) or with 100 μM
SFLLRN (SF) for 60 min at 37°C, ﬁxed, permeabilized, and incubated
with anti-FLAG and -LAMP1 antibodies. Immunolabeled cells were processed and imaged by confocal microscopy. The colocalization of PAR1
and LAMP1 is shown in yellow in the merged image and is representative
of many cells examined in three independent experiments. Insets show
magniﬁcations of boxed areas. Bars, 10 μm. The data (mean ± SD) represent Pearson’s correlation coefﬁcients that were calculated for PAR1 and
LAMP1 colocalization for control versus agonist-stimulated conditions and
were signiﬁcant, as determined by Student’s t test (***, P < 0.001; n = 6).
(B and C) HeLa cells expressing FLAG-PAR1 WT or 0K mutant were prelabeled with anti-FLAG antibody for 1 h at 4°C and then stimulated with
100 μM SFLLRN for 20 min at 37°C. Cells were ﬁxed and processed for
immuno-EM. Dual-labeled ultrathin sections revealed that PAR1 WT and 0K
mutant detected with 12-nm gold-conjugated secondary antibody (black
arrows) sorted to ILVs present in CD63-positive MVBs, which was detected
with 6-nm gold-labeled secondary antibody (white arrows). Bar, 100 nm.

by examining its colocalization with the lysosomal-associated
membrane protein 1 (LAMP1) in HeLa cells using immunofluorescence confocal microscopy. In the absence of agonist
stimulation, PAR1 WT and 0K mutant cycle constitutively
between the plasma membrane and early endosomes (Paing et al.,
2006; Wolfe et al., 2007). Consistent with these studies, we
found that PAR1 WT and 0K mutant localized predominantly
to the cell surface and early endosomes and showed no significant colocalization with LAMP1 under control conditions
(Figs. 1 A and S1 A). However, after 60 min of agonist stimulation, PAR1 WT colocalized extensively with LAMP1-positive
vesicles (Fig. 1 A), as previously reported (Trejo et al., 2000).
Activation of PAR1 0K mutant with agonist for 60 min also
resulted in substantial receptor colocalization with LAMP1
(Fig. 1 A). The colocalization of activated PAR1 WT and 0K
mutant with LAMP1 was verified by determining Pearson’s
correlation coefficient for PAR1 WT (r = 0.30 ± 0.05; n = 6)
and 0K mutant (r = 0.30 ± 0.08; n = 6). Thus, after activation,
PAR1 0K mutant is efficiently sorted to lysosomes like WT
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ILVs and ILV formation (Wollert and Hurley, 2010). ESCRT-III
polymerizes on endosomal membranes and is the main driver
of ILV scission. The AAA-ATPase vacuolar protein sorting 4
(Vps4) disassembles and recycles ESCRT-III components and
is essential for ESCRT function. In addition to receptor sorting
at the MVB, ESCRT mediates viral budding and cytokinesis
through processes that require ESCRT-I and -III and ALIX,
an ESCRT-III–interacting protein, but not ESCRT-0 or -II (Strack
et al., 2003; Carlton et al., 2008). Whether there are differences
in ESCRT requirements for the sorting of signaling receptors
at the MVB in mammalian cells remains unclear.
Most GPCRs require posttranslational modification with
ubiquitin and ESCRTs for sorting from endosomes to lysosomes. The chemokine receptor CXCR4 is ubiquitinated after
activation and sorted from endosomes to lysosomes through a
pathway that requires HRS and Vps4 (Marchese et al., 2003).
PAR2, a GPCR related to PAR1, also undergoes agonist-induced
ubiquitination and is sorted to lysosomes through an HRSdependent pathway (Hasdemir et al., 2007). However, not all
GPCRs require direct ubiquitination for MVB sorting and lysosomal degradation, as exemplified by the D-opioid receptor (DOR).
A ubiquitination-deficient DOR mutant is efficiently sorted to
ILVs of MVBs similar to wild-type (WT) receptor (Henry et al.,
2011). However, degradation of DOR requires HRS and Vps4
but not Tsg101 (Hislop et al., 2004), indicating that receptor
sorting can occur independent of ubiquitination and requires
some but not all components of the ubiquitin-binding ESCRT
machinery. Thus, it remains to be determined whether a signaling receptor can bypass the requirement for both ubiquitination
and ubiquitin-binding components of the ESCRT machinery
and sort to MVBs/lysosomes.
We previously showed that activated PAR1 is efficiently
sorted from endosomes to lysosomes and degraded independent
of ubiquitination (Wolfe et al., 2007). In contrast to DOR, however, neither HRS nor Tsg101 is essential for lysosomal degradation of PAR1 (Gullapalli et al., 2006). Thus, it is not known
whether activated PAR1 ultimately sorts to ILVs of MVBs and
requires any components of the ESCRT machinery for lysosomal degradation. Here, we report that activated PAR1 sorts
to ILVs of MVBs through a pathway that requires ALIX and
ESCRT-III function but not receptor ubiquitination. Moreover,
our findings indicate that ALIX binds to a YPX3L motif of PAR1
and recruits ESCRT-III to mediate MVB/lysosomal sorting.

Published April 30, 2012

ESCRT-III and Vps4 mediate PAR1
lysosomal degradation

To define the ubiquitin-independent lysosomal degradation
pathway of PAR1, we examined the function of ESCRT-III
components, which do not contain any known ubiquitin-binding
domains (Hurley and Hanson, 2010). Charged MVB protein 4
(CHMP4) is the most abundant subunit of ESCRT-III, which
serves as the critical mediator of ILV scission, and exists as
three isoforms: CHMP4A, B, and C (Wollert and Hurley,
2010). We first determined the expression of CHMP4 isoforms
in HeLa cells using RT-PCR and CHMP4 isoform–specific
primers (Fig. 2 A, lanes 6–8). RT-PCR assay of HeLa cell RNA
revealed the presence of all three isoforms, including CHMP4A,
B, and C (Fig. 2 A, lanes 1 and 2). To assess CHMP4 function
in PAR1 degradation, siRNAs that specifically target each of the
three CHMP4 isoforms expressed in HeLa cells were used.
HeLa cells transfected with CHMP4 isoform–specific siRNA
SMARTpools exhibited a substantial decrease in CHMP4A, B,
and C mRNA transcripts, as revealed by RT-PCR (Fig. 2 A,
lanes 3–5). Consistent with diminished mRNA transcripts,
CHMP4-specific siRNAs also caused significant depletion of
endogenous CHMP4A and CHMP4B protein, as detected by
immunoblotting (Fig. 2 B). Because there are no anti-CHMP4C
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receptor, suggesting that ubiquitination is not essential for
PAR1 lysosomal sorting.
A critical step in lysosomal sorting and degradation of
most proteins in mammalian cells requires incorporation into
ILVs of the MVB. To determine whether PAR1 directly enters
ILVs of MVBs independent of receptor ubiquitination, we performed immuno-EM on ultrathin cryosections of HeLa cells
expressing PAR1 WT or ubiquitin-deficient 0K mutant. To examine endocytic sorting of the cell surface cohort of PAR1 WT
and 0K mutant after agonist activation, receptors were prelabeled with anti-FLAG antibody at 4°C and then treated with
agonist for 20 min. After agonist stimulation, activated PAR1 WT
(12-nm gold particles) sorted to an endosomal compartment
that colabeled with the late endosome/MVB marker CD63 (6-nm
gold particles; Fig. 1 B), suggesting that activated PAR1 traffics
to MVBs. Remarkably, the ubiquitination-deficient PAR1 0K
mutant also localized to ILVs of CD63-positive MVBs after agonist activation (Fig. 1 C), indicating that PAR1 traffics to ILVs
of MVBs independent of receptor ubiquitination. To ensure that
antibody prelabeling did not alter the internalization and sorting
of PAR1, we examined the colocalization of PAR1 WT and 0K
mutant with LAMP1 by immunofluorescence confocal microscopy in parallel. As expected, PAR1 WT and 0K mutant localized to the cell surface and early endosomes and did not
colocalize with LAMP1 after incubation for 20 min in the absence of agonist (Fig. S1, B and C). In contrast, however, stimulation of PAR1 WT and 0K mutant with agonist for 20 min
caused significant colocalization with LAMP1 (Fig. S1, B and C),
consistent with that observed in cells not prelabeled with antibody (Fig. 1 A). Together, these data demonstrate that ubiquitination of activated PAR1 is not required for entry into ILVs
of MVBs and suggest that a novel pathway exists for the sorting
of nonubiquitinated receptors to the lysosome.

Figure 2. CHMP4 mediates PAR1 lysosomal degradation. (A) RT-PCR assays of HeLa RNA using CHMP4A, B, or C isoform–speciﬁc primers. No
RT is indicated (). RNA isolated from HeLa cells transfected with 100 nM
CHMP4A-, B-, or C-speciﬁc siRNAs was subject to RT-PCR. As a control,
1 ng CHMP4A, B, and C cDNA plasmids was ampliﬁed by RT-PCR in parallel. The asterisk indicates a nonspeciﬁc band. (B) HeLa cells expressing
FLAG-PAR1 were transfected with 100 nM of nonspeciﬁc (ns) or CHMP4
isoform–speciﬁc siRNAs and stimulated with 100 μM SFLLRN for 60 min at
37°C, and PAR1 degradation was assessed. Cell lysates were immunoblotted (IB) with anti-CHMP4A, -CHMP4B, and -actin antibodies. The data
(mean ± SD) are expressed as the fraction of PAR1 remaining compared
with untreated control (Ctrl). The amount of PAR1 detected in CHMP4B and
CHMP4C siRNA–treated cells was signiﬁcantly different from nonspeciﬁc
siRNA-treated cells, determined by a two-way analysis of variance (*, P <
0.05; ***, P < 0.001; n = 3).

antibodies commercially available, we were unable to examine endogenous CHMP4C protein expression in siRNA-transfected cells.
To assess the function of CHMP4 in PAR1 degradation,
HeLa cells expressing FLAG-PAR1 were transfected with either nonspecific or CHMP4-specific siRNAs. Cells were then
incubated with agonist for 60 min, and PAR1 degradation was
assessed. In nonspecific siRNA-transfected cells, an Y50% decrease in the amount of PAR1 protein was detected after 60 min
of agonist incubation compared with unstimulated control cells
(Fig. 2 B, lanes 1 and 2). The extent of PAR1 degradation was
similar in nonspecific and CHMP4A siRNA–transfected cells
after agonist stimulation, suggesting that CHMP4A is not essential for PAR1 degradation (Fig. 2 B, lanes 1–4). In contrast,
agonist-induced degradation of PAR1 was significantly inhibited in cells transfected with either CHMP4B or CHMP4C
siRNA SMARTpools (Fig. 2 B, lanes 5–8), indicating that both
CHMP4B and C isoforms are necessary for PAR1 degradation.
Cells transfected with single siRNAs targeting CHMP4B resulted
in loss of endogenous CHMP4B expression and also blocked
agonist-promoted PAR1 degradation (Fig. S2). These results
ALIX-dependent GPCR lysosomal sorting • Dores et al.
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Figure 3. PAR1 does not accumulate in Vps4 E228Q–positive endosomes. (A and B) HeLa cells expressing FLAG-PAR1 or FLAG-PAR2 were
transfected with either Vps4-GFP or Vps4 E228Q–GFP. Cells were stimulated with 100 μM SFLLRN or 100 μM SLIGKV, as indicated, and lysed,
and equivalent amounts of lysates were immunoprecipitated (IP), and
PAR degradation was assessed by immunoblotting (IB). Cell lysates were
immunoblotted with anti-GFP and -actin antibodies. The data (mean ± SD) are
expressed as the fraction of PAR1 remaining compared with untreated
control (Ctrl) and were analyzed by a two-way analysis of variance
(**, P < 0.01; ***, P < 0.001; n = 3). (C and D) HeLa cells expressing FLAG-PAR1 or FLAG-PAR2 and either GFP-tagged Vps4 or E228Q
mutant were prelabeled with anti-FLAG antibody for 1 h at 4°C, washed,
and stimulated with 100 μM SFLLRN or 100 μM SLIGKV at 37°C, as
indicated. Cells were ﬁxed, permeabilized, and immunostained for PAR1
and CD63. Cells coexpressing PAR1 or PAR2 and either Vps4 WT or
E228Q mutant are indicated by the arrowheads. The insets are magniﬁcations of the boxed areas. Bars, 10 μm.

the time course for agonist-induced PAR1 localization to ILVs
of MVBs and suggest that CHMP4B is a component of the
ESCRT-III complex that binds to activated PAR1. Next, we
examined PAR1 interaction with CHMP4C in HeLa cells transfected with an HA-tagged CHMP4C, as CHMP4C antibodies are
not available. HeLa cells coexpressing FLAG-PAR1 and
HA-CHMP4C were incubated with agonist for various times,
PAR1 was immunoprecipitated, and CHMP4C association
was assessed. In unstimulated control cells, CHMP4C failed
to interact with PAR1 (Fig. 4 B). However, after activation of
PAR1 for 10 min, a marked increase in CHMP4C association
with PAR1 was detected (Fig. 4 B). Next, we examined
whether the ubiquitin-deficient PAR1 0K mutant interacted
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suggest that CHMP4 mediates agonist-induced PAR1 lysosomal degradation.
The AAA-ATPase Vps4 catalyzes ESCRT-III disassembly and recycling and is critical for ESCRT function (Hurley
and Hanson, 2010). To examine the role of Vps4 in agonistinduced PAR1 degradation, we used a catalytically inactive
Vps4 E228Q variant, which functions as a dominant-negative
mutant (Babst et al., 1998; Bishop and Woodman, 2000).
HeLa cells coexpressing PAR1 and either Vps4 WT or E228Q
mutant fused to GFP were incubated with agonist, and receptor degradation was assessed. Interestingly, agonist-promoted
PAR1 degradation was significantly inhibited in cells coexpressing Vps4 E228Q mutant compared with Vps4 WT–
expressing cells (Fig. 3 A), indicating that Vps4 mediates
MVB sorting of PAR1. Agonist-promoted PAR2 degradation
was similarly inhibited in Vps4 E228Q mutant–expressing
cells compared with control cells expressing WT Vps4 (Fig. 3 B).
PAR1 and PAR2 degradation induced by agonist was also inhibited in cells transfected with siRNAs targeting both Vps4A
and B isoforms (Fig. S3, A and B). These results suggest that
Vps4 is required for both ubiquitin- and nonubiquitin-mediated
lysosomal sorting of GPCRs.
Next, we evaluated Vps4 function in MVB/lysosomal
sorting of activated PAR1 and PAR2 by immunofluorescence
confocal microscopy. Cells coexpressing FLAG-PAR1 or
FLAG-PAR2 and either Vps4 WT or E228Q mutant fused to
GFP were incubated with anti-FLAG antibody at 4°C to ensure
only the cell surface receptors would be labeled and then stimulated with agonist. In the absence of agonist, PAR1 and
PAR2 localized predominantly to the cell surface, whereas
agonist-stimulated PAR1 and PAR2 redistributed from the
cell surface to endosomes (Fig. 3, C and D). As expected, coexpression of Vps4 E228Q mutant resulted in accumulation of
internalized PAR2 in enlarged vesicles, defined as a class E
phenotype that results from disruption of ESCRT-III recycling
(Fig. 3 D; Babst et al., 1998; Bishop and Woodman, 2000). In
contrast, PAR1-containing endosomes were unperturbed in
Vps4 E228Q mutant–expressing cells and appeared similar to
those in adjacent untransfected cells and cells expressing Vps4
WT (Fig. 3 C). Aberrant localization of CD63 observed in
cells coexpressing PAR1 and Vps4 E228Q mutant indicates
disruption of the MVB compartment (Fig. 3 C). Thus, in contrast to ubiquitinated cargo, PAR1 fails to accumulate at the
MVB when the pathway is disrupted, suggesting that MVB
sorting of PAR1 is distinctly regulated.
To confirm ESCRT-III function in PAR1 lysosomal degradation, we examined whether activated PAR1 forms a complex with CHMP4. We first assessed the coassociation of
endogenous CHMP4B with activated PAR1 in HeLa cells by
coimmunoprecipitation. HeLa cells expressing FLAG-PAR1
WT were incubated with agonist for various times, PAR1 was
immunoprecipitated, and association of CHMP4B was examined. In the absence of agonist, PAR1 and CHMP4B interaction was undetectable (Fig. 4 A). However, an interaction
between PAR1 and endogenous CHMP4B was detected after
10 min of agonist stimulation, and the proteins remained associated for Y20 min (Fig. 4 A). These findings coincide with
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with CHMP4 proteins. Similar to WT PAR1, both CHMP4B
and CHMP4C coimmunoprecipitated with activated PAR1 0K
mutant after 10 min of agonist stimulation (Fig. 4 C), indicating that CHMP4B and CHMP4C are components of the PAR1
ubiquitin–independent sorting complex. In contrast, FLAGtagged B2-adrenergic receptor (B2AR), a classical GPCR, failed
to coimmunoprecipitate with HA-CHMP4B or HA-CHMP4C
in PAR1-expressing cells stimulated with the PAR1-specific
agonist for 10 min (Fig. 4 D). Together, these findings demonstrate that ESCRT-III binds specifically to activated PAR1
and regulates MVB/lysosomal degradation.
The ESCRT-III–associated protein ALIX
is required for PAR1 degradation

To further define the PAR1 ubiquitin–independent lysosomal
sorting pathway, we investigated the function of ALIX, a CHMP4interacting protein that recruits ESCRT-III to membranes (Fisher
et al., 2007). We first examined whether PAR1 interacted with
endogenous ALIX in HeLa cells. Cells expressing FLAG-PAR1
were stimulated with agonist for various times, PAR1 was immunoprecipitated, and association of endogenous ALIX was
assessed. In cells treated with agonist for 10 min, PAR1 association with endogenous ALIX was markedly increased compared
with untreated control cells (Fig. 5 A, lanes 1 and 2), whereas
PAR1 and ALIX interaction was diminished after 20 min of
agonist exposure (Fig. 5 A, lanes 1–3). In contrast, PAR2 and
ALIX interaction was negligible in control and agonist-treated
cells (Fig. 5 A, lanes 4 and 5). PAR1 also associated with
HA-ALIX in an agonist-dependent manner (Fig. S4 A), whereas
HA-ALIX failed to bind to B2AR in cells treated with PAR1specific agonist (Fig. S4 B) or to activated PAR2 (Fig. S4 C).
Next, we examined the association of endogenous ALIX with
ubiquitination-deficient PAR1 in HeLa cells. In contrast to control
cells, activation of the PAR1 0K mutant for 10 min resulted in
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Figure 4. Activated PAR1 coassociates with
CHMP4. (A) HeLa cells expressing FLAG-PAR1
were stimulated with 100 μM SFLLRN for
various times at 37°C. Equivalent amounts
of cell lysates were immunoprecipitated (IP)
with anti-PAR1 antibody, and the presence of
endogenous CHMP4B was determined by
immunoblotting (IB). Cell lysates were immunoblotted with anti-CHMP4B and -actin antibodies.
(B and C) HeLa cells expressing FLAG-PAR1
(B) or FLAG-PAR1 0K (C) and coexpressing
HA-CHMP4C or HA-CHMP4B were stimulated
with 100 μM SFLLRN at 37°C, as indicated.
Equivalent amounts of cell lysates were immunoprecipitated with M2 anti-FLAG antibody or
IgG control, and the presence of FLAG-PAR1 or
PAR1 0K and associated HA-CHMP4 was determined by immunoblotting. Cell lysates were
immunoblotted with anti-HA and -actin antibodies. (D) PAR1-expressing HeLa cells were
cotransfected with FLAG-tagged B2-adrenergic
receptor (B2AR) and either HA-CHMP4B or
HA-CHMP4C and stimulated with 100 μM
SFLLRN at 37°C for 10 min. FLAG-B2AR was
immunoprecipitated with anti-FLAG antibody,
and immunoprecipitates were analyzed by
immunoblotting using anti-HA antibodies. Cell
lysates were immunoblotted with anti-HA
and -actin antibodies as controls.

endogenous ALIX association (Fig. 5 B), suggesting that
ubiquitination is not required for ALIX interaction with activated PAR1.
ALIX has been shown to link certain viral proteins to the
ESCRT-III complex, a process important for viral budding (Usami
et al., 2007). Therefore, we examined whether ALIX was required for agonist-induced PAR1 interaction with CHMP4.
HeLa cells coexpressing FLAG-PAR1 and HA-CHMP4B
transfected with nonspecific or ALIX-specific siRNAs were
treated with agonist, PAR1 was immunoprecipitated, and CHMP4
association was assessed. In nonspecific siRNA control cells, a
10-min incubation with agonist resulted in robust PAR1 association with CHMP4B (Fig. 5 C, lanes 1–4). In striking contrast,
activated PAR1 interaction with CHMP4B was virtually ablated in ALIX-deficient cells (Fig. 5 C, lanes 5–8). These findings suggest that ALIX links PAR1 to the ESCRT-III machinery
to facilitate lysosomal sorting.
Next, we assessed ALIX function in agonist-induced
PAR1 lysosomal degradation. HeLa cells expressing FLAGPAR1 were transfected with ALIX-specific siRNAs and stimulated with agonist for various times, and PAR1 degradation
was examined. In ALIX-deficient cells, agonist-promoted
degradation of PAR1 was significantly inhibited compared
with the extent of PAR1 degradation observed after 60 min of
agonist stimulation in siRNA-treated control cells (Fig. 6 A).
However, internalization of activated PAR1 occurred normally
in ALIX-deficient cells (Fig. S4 D), indicating that ALIX mediates PAR1 sorting to a lysosomal degradative pathway after
internalization. Depletion of endogenous ALIX expression
also caused a significant defect in agonist-promoted degradation of endogenous PAR1-expressed human endothelial
cells (Fig. 6 B). Moreover, agonist-induced degradation of
ubiquitination-deficient PAR1 0K mutant was also impaired
in ALIX-deficient cells, whereas activated PAR2 degradation
ALIX-dependent GPCR lysosomal sorting • Dores et al.
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ALIX binds to a highly conserved YPXnL
motif in PAR1 via its central V domain

remained intact (Fig. 6 C). Together, these findings support a
function for ALIX in ubiquitin-independent MVB sorting of
activated PAR1.
To confirm that ALIX is required for PAR1 degradation,
we performed knockdown rescue experiments in cells cotransfected with two siRNAs targeting endogenous ALIX together
with FLAG-tagged PAR1 and an siRNA-resistant HA-ALIX
WT variant. In cells depleted of endogenous ALIX, agonistinduced degradation of PAR1 was significantly impaired compared with siRNA-treated control cells (Fig. 6 D, lanes 1–4).
However, coexpression of siRNA-resistant HA-ALIX WT
restored activated PAR1 degradation in cells lacking endogenous ALIX (Fig. 6 D, lanes 5 and 6). In contrast, agonist failed
to induce PAR1 degradation in cells depleted of endogenous
ALIX and expressing an siRNA-resistant HA-ALIX Bro domain deletion mutant (Fig. 6 D, lanes 7 and 8). The N-terminal
Bro domain of ALIX mediates interaction with CHMP4 (Kim
et al., 2005). These findings suggest that ALIX-mediated
MVB/lysosomal sorting of PAR1 requires interaction with
CHMP4 and is a distinct pathway from that used by ubiquitinated GPCRs.
412
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Figure 5. ALIX associates with PAR1 and mediates interaction with
CHMP4. (A and B) HeLa cells expressing either FLAG-tagged PAR1 WT,
0K mutant, or PAR2 were stimulated with 100 μM SFLLRN or 100 μM
SLIGKV for various times at 37°C. Equivalent amounts of cell lysates
were immunoprecipitated (IP) and examined as described in Fig. 4 B. IB,
immunoblotting. (C) HeLa cells expressing FLAG-PAR1 were cotransfected
with HA-CHMP4B and either 100 nM nonspeciﬁc (ns) or ALIX-speciﬁc
siRNAs. Equivalent amounts of cell lysates were immunoprecipitated and
analyzed as described in Fig. 4 B.

ALIX contains an N-terminal Bro1 domain, a central V domain,
and C-terminal proline-rich region. ALIX binds to YPXnL motifs
present in the late domain of viral Gag proteins via its central V
domain (Fisher et al., 2007; Zhai et al., 2008) and is critical for
ESCRT-III recruitment and viral budding (Usami et al., 2007).
A search of the PAR1 cytoplasmic domains for such a sequence
revealed a highly conserved motif within the second intracellular
loop of the receptor (Fig. 7 A). The PAR1 Y206PMQSL211 motif
conforms to the ALIX-binding motif YPXnL (with n = 3) and is
not present in PAR2 cytoplasmic domains (Fig. 7 A). A search of
several hundred class A GPCRs for such a motif revealed the
presence of a highly conserved sequence that conforms to the
YPXnL motif residing in the second intracellular loop of seven
other mammalian GPCRs (Table 1). Only one class A GPCR
harbors a conserved YPXnL motif within the cytoplasmic tail
domain (Table 1). To examine the importance of the YPX3L
motif in PAR1 degradation, we mutated the critical Y206 to alanine, as analogous Y mutations in YPXnL motifs of viral Gag
proteins abrogated ALIX interaction and function (Strack et al.,
2003). The PAR1 Y206A mutant expressed at the surface and
internalized after activation comparable with WT PAR1 (Fig. S5,
A and B), suggesting that the PAR1 Y206A mutant traffics to
and from the cell surface normally.
Next, we examined whether the PAR1 YPX3L motif was
necessary for interaction with ALIX. HeLa cells coexpressing
FLAG-PAR1 WT or Y206A mutant together with HA-ALIX
were stimulated with agonist, and coassociation was examined.
PAR1 WT robustly associated with ALIX after 10 min of agonist
stimulation, whereas activated PAR1 Y206A mutant interaction
with ALIX was negligible (Fig. 7 B). PAR2, which lacks a
YPXnL motif, also failed to bind to HA-ALIX (Fig. S4 C), suggesting that the YPXnL motif is an important determinant for
ALIX interaction. We also examined whether the ALIX V domain is required for association with PAR1. The ALIX central V
domain binds directly to YPXnL sequences of viral Gag proteins,
and mutation of the critical phenylalanine to aspartic acid (F676D)
was shown to disrupt this interaction (Zhai et al., 2008). In contrast to PAR1 interaction with WT ALIX, the HA-ALIX F676D
mutant failed to bind to PAR1 after 10 min of agonist incubation
(Fig. 7 C). To confirm direct interaction between the PAR1
YPX3L motif and the ALIX V domain, we performed in vitro
binding assays using a biotinylated PAR1 ICL2 peptide containing the YPX3L motif in pull-down experiments with purified
GST-tagged ALIX. Strikingly, the ALIX V domain showed robust interaction with the PAR1 YPX3L containing ICL2 peptide
(Fig. 7 D), whereas neither the ALIX V domain harboring the
F676D mutant nor the ALIX Bro1 domain bound to the PAR1
ICL2 peptide (Fig. 7 D). Together, these findings strongly suggest that ALIX can bind directly to the YPX3L motif of PAR1 via
its central V domain.
Our experiments indicate that the PAR1 YPX3L motif is
critical for binding to ALIX. Therefore, we tested whether the
PAR1 YPX3L motif was necessary for agonist-promoted PAR1
degradation. Incubation with agonist for 60 min caused an
Y50% loss of PAR1 protein (Fig. 8 A). In contrast to WT
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PAR1, agonist-stimulated degradation of the PAR1 Y206A
mutant was significantly inhibited (Fig. 8 A). Next, we examined whether PAR1 Y206A mutant remained at the limiting
membrane of MVBs or sorted to an internal compartment by
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Figure 6. ALIX is required for agonistinduced PAR1 degradation. (A and C) HeLa
cells expressing FLAG-tagged PAR1 (A), PAR1
0K mutant, or PAR2 (C) were transfected
with 100 nM nonspeciﬁc (ns) or ALIX-speciﬁc
siRNAs and stimulated with 100 μM SFLLRN
or 100 μM SLIGKV at 37°C, as indicated. PAR
degradation was assessed by immunoblotting
(IB). The data (mean ± SD) are expressed as
the fraction of PAR1 remaining compared with
untreated control (Ctrl) and were analyzed by a
two-way analysis of variance (*, P < 0.05; n = 3).
(B) Human endothelial cells transfected with
100 nM of nonspeciﬁc or ALIX-speciﬁc siRNAs
stimulated with 100 μM TFLLRNPNDK at 37°C,
as indicated, and immunoprecipitated (IP) with
anti-PAR1 or IgG antibodies (Ab). Endogenous
PAR1 was detected by immunoblotting. Cell
lysates were immunoblotted with anti-ALIX
and -actin antibodies. The data (mean ± SD) are
expressed as a fraction of untreated control and
were analyzed by a two-way analysis of variance (*, P < 0.05; n = 3). (D) HEK293 cells
cotransfected with either 100 nM of nonspeciﬁc
or two ALIX-speciﬁc siRNAs together with FLAGPAR1 and either siRNA-resistant HA-ALIX WT or
HA-ALIX Bro1$ were incubated with or without
100 μM SFLLRN for 50 min at 37°C. Equivalent
amounts of lysates were analyzed for PAR1, endogenous ALIX (lanes 1–4), HA-ALIX WT (lanes
5 and 6), or HA-ALIX Bro1$ (lanes 7 and 8)
expression by immunoblotting.

evaluating its sensitivity to proteinase K digestion after activation and internalization. Proteinase K protection assays have
been used previously to assess EGFR sorting to ILVs of MVBs
(Malerød et al., 2007). HeLa cells expressing PAR1 WT or

Figure 7. A YPX3L motif of PAR1 mediates binding to ALIX. (A) Alignment of PAR1 and PAR2 ICL2
sequences from various species. The conserved
residues of the YPX3L motif are shaded in gray.
(B) HeLa cells coexpressing HA-ALIX WT and either
FLAG-PAR1 WT or Y206A mutant were stimulated
with 100 μM SFLLRN at 37°C, as indicated. Cell
lysates were immunoprecipitated and examined
as described in Fig. 4 B. IB, immunoblotting. The
data (mean ± SD) represent the amount of immunoprecipitated ALIX normalized to the amount of
immunoprecipitated PAR1 and were signiﬁcant,
as determined by Student’s t test (**, P < 0.01;
n = 3). A.U., arbitrary unit. (C) HeLa cells transfected with FLAG-PAR1 and either HA-ALIX WT or
F676D mutant were stimulated with agonist and
processed as previously described. Cell lysates
were immunoblotted with anti-HA and -actin antibodies. The data (mean ± SD) were calculated,
as previously described, and signiﬁcant, as determined by Student’s t test (**, P < 0.01; n = 3).
(D) Biotinylated PAR1 ICL2 peptide containing
the YPX3L motif was immobilized on streptavidin
beads and incubated with GST, GST–ALIX V domain, GST–ALIX V F676D, or the GST–ALIX Bro1
domain. Pulldowns (PD) were analyzed for the
presence of bound protein by immunoblotting. Input
was analyzed by Coomassie staining.
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Table 1.

Human GPCRs with conserved YPXnL motifs

Family
Adrenoceptors
Angiotensin
Galanin
Histamine
Neuropeptide FF
Neuropeptide S
Protease activated
P2Y
Melanocortin

IUPHAR nomenclature

NCBI Protein database
accession no.

YPXnL location

A1B Adrenoceptor
AT2
GAL2
H2
NPFF2
NPS receptor
PAR1
P2Y1
MC4

P35368
P50052
O43603
P25021
A0PJM9
Q6W5P4
P25116
P47900
P32245

ICL2
ICL2
ICL2
ICL2
ICL2
ICL2
ICL2
ICL2
Cytoplasmic tail

Sequence
141-DRYIGRYSLQYPTLVT-158
140-DRYQSVIYPFLSQRRN-157
121-DRYLAIRYPLHSRELRT-139
114-DRYCAVMDPLRYPVLVT-132
141-DRFQCVVYPFKPKLTIK-159
144-DRYHAIVYPMKFLQGE-161
198-DRFLAVVYPMQSLSWRT-216
147-HRYSGVVYPLKSLGRLK-165
318-YPLGGLCDLSSRY-stop

A search of 397 class A GPCR cytoplasmic sequences for YPXnL motifs was completed by sequence alignment using the GPCR database (Vroling et al., 2011). Of
these, several GPCRs contained sequences conforming to the YPXnL motif in the ICL2 (bold) and were aligned starting with the DRY/F motif. The list includes the GPCR
family name, International Union of Basic and Clinical Pharmacology (IUPHAR) nomenclature, and NCBI accession numbers.

Figure 8. The YPX3L motif of PAR1 is essential for
MVB/lysosomal sorting. (A) HeLa cells expressing
FLAG-PAR1 WT or Y206A mutant were incubated
with 100 μM SFLLRN at 37°C, as indicated. PAR1
degradation was analyzed as described in Fig. 2 B.
IB, immunoblotting. The data (mean ± SD) are
expressed as a fraction of untreated control (Ctrl)
and were analyzed by a two-way analysis of
variance (*, P < 0.05; ***, P < 0.001; n = 3).
(B) HeLa cells expressing FLAG-PAR1 WT or Y206A
were untreated (control) or treated with 100 μM
SFLLRN (SF) for 15 min at 37°C. Membranes were
isolated and treated with proteinase K or proteinase K with 0.1% Triton X-100, and PAR1 or EEA1
was detected by immunoblotting. The data (mean ±
SD) are expressed as the fraction of PAR1 remaining after proteinase K treatment compared
with untreated control () from either the control or
SFLLRN (+SF)-treated samples and were analyzed
by Student’s t test (*, P < 0.05; n = 3). (C and D)
HeLa cells expressing either FLAG-PAR1 WT or
Y206A mutant were prelabeled with anti-FLAG antibody at 4°C and incubated with 100 μM SFLLRN
at 37°C, as indicated. Cells were immunostained
for either EEA1 or LAMP1 and analyzed, as described in Fig. 1 A. Insets show magniﬁcations of
boxed areas. Bars, 10 μm. The data (mean ± SD)
represent Pearson’s correlation coefﬁcients that
were calculated, as described in Fig. 1 A, and
were analyzed by Student’s t test (**, P < 0.01;
***, P < 0.001; n = 6).

414

JCB • VOLUME 197 • NUMBER 3 • 2012

were efficiently degraded after exposure to proteinase K in samples supplemented by Triton X-100, which allows proteinase K
access to internal membranous compartments (Fig. 8 B, lanes 3, 6,
9, and 12). The early endosomal antigen protein 1 (EEA1) was also
efficiently degraded in all proteinase K–treated samples, demonstrating effective plasma membrane permeabilization and proteinase K activity (Fig. 8 B). In addition, the PAR1 Y206A
mutant internalized to EEA1-positive endosomes like WT receptor in cells treated with agonist for 10 min (Fig. 8 C), and
both sorted from the EEA1-containing endosomes after 20 min
(Fig. 8 C). The extent of colocalization with EEA1 at 10 min was
quantified by determining the Pearson’s correlation coefficient for
PAR1 WT (r = 0.50 ± 0.1; n = 6) and Y206A (r = 0.43 ± 0.09;
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Y206A mutant were incubated with agonist for 15 min at 37°C,
washed, and gently permeabilized with digitonin. Membranes
were isolated, divided into aliquots, and either left untreated,
treated with proteinase K, or treated with proteinase K supplemented with 0.1% Triton X-100. Activation of PAR1 WT
resulted in a greater accumulation of receptor in proteinase K–
treated samples compared with unstimulated control samples
(Fig. 8 B, lanes 2 and 5), indicating that activated PAR1 WT is
sorted into protective endosomal compartments. In contrast,
PAR1 Y206A mutant failed to accumulate in protective endosomal
compartments compared with unstimulated control (Fig. 8 B,
lanes 8 and 11), suggesting the PAR1 Y206A mutant is defective
in MVB sorting. However, both PAR1 WT and Y206A mutant
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n = 6). Interestingly, however, PAR1 Y206A mutant showed
minimal colocalization with LAMP1 after 20 min of agonist
stimulation compared with WT PAR1 (Fig. 8 D), which was
verified by Pearson’s correlation coefficient for PAR1 WT (r =
0.28 ± 0.08; n = 6) and Y206A (r = 0.08 ± 0.02; n = 6). Thus,
the YPX3L motif is a critical determinant for PAR1 ubiquitin–
independent MVB/lysosomal sorting (Fig. 9).

Discussion
In this study, we define a new ubiquitin-independent MVB/
lysosomal sorting pathway for signaling receptors that requires
ALIX and ESCRT-III function in mammalian cells. We demonstrate that activated PAR1 is sorted to ILVs of MVBs independent of receptor ubiquitination but requires ESCRT-III function.
Our data further indicate that PAR1 degradation is regulated by
ALIX, which binds directly to a YPX3L motif localized within
the PAR1’s intracellular loop via its central V domain and mediates CHMP4/ESCRT-III recruitment to the receptor. Thus,
PAR1 bypasses the requirement for ubiquitination and ubiquitinbinding ESCRTs but requires ALIX and ESCRT-III for sorting
to ILVs of MVBs (Fig. 9).
We previously showed that lysosomal sorting of PAR1
occurs independent of ubiquitination and the ubiquitin-binding
ESCRT components HRS and Tsg101 (Gullapalli et al., 2006;
Wolfe et al., 2007), but whether PAR1 sorts to ILVs of MVBs
remained unknown. Here, we show that a ubiquitination-deficient
PAR1 mutant sorted to ILVs similar to WT receptor, indicating
that ubiquitination is not essential for ILV sorting of PAR1. Our
experiments further indicate that CHMP4, the major subunit of
ESCRT-III and driver of ILV scission, is essential for agonistinduced PAR1 degradation. In contrast to other ESCRT complexes, ESCRT-III does not contain any known ubiquitin-binding
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Figure 9. GPCR ubiquitin-dependent and -independent MVB sorting. The
ubiquitin-mediated MVB sorting pathway of PAR2 requires the ESCRT-0,
-I, and -II complexes before ESCRT-III–mediated incorporation into ILVs. In
contrast, PAR1 MVB sorting is mediated by ALIX recruitment of the ESCRT-III
complex, independent of ubiquitination (Ub).

subunits, suggesting that ubiquitin binding is not essential for
ESCRT-III–mediated PAR1 degradation. Moreover, ubiquitination is not a prerequisite for cargo passage into ILVs, as ESCRT-III
subunits recruit enzymes that appear to deubiquitinate cargo
before ILV entry (Kyuuma et al., 2007). Thus, unlike most
cargo sorted to ILVs of MVBs via the canonical ESCRT pathway,
our findings indicate that PAR1 is uniquely sorted by ESCRT-III
independent of ubiquitination. This pathway is also distinct
from the entirely ESCRT-independent ILV sorting pathway previously described for the melanosome constituent Pmel and the
proteolipid protein (Theos et al., 2006; Trajkovic et al., 2008;
van Niel et al., 2011). Other cargo, such as the yeast Sna3 and
mammalian DOR, are also not directly ubiquitinated, but certain
ubiquitin-binding ESCRT components facilitate MVB/lysosomal
sorting (Hislop et al., 2004; McNatt et al., 2007; Oestreich et al.,
2007; Watson and Bonifacino, 2007).
Our findings also reveal a novel function for ALIX, a
CHMP4–ESCRT-III interacting protein, in mediating MVB/
lysosomal sorting of PAR1. ALIX directly binds to and recruits
CHMP4–ESCRT-III to membranes via interaction with its Bro
domain and is important for abscission during cytokinesis and
budding of certain viruses (Strack et al., 2003; Morita et al.,
2007). However, ALIX function in cargo sorting at MVBs in
mammalian cells is not known. Bro1, the yeast homolog of
ALIX, facilitates the sorting of ubiquitinated cargo at MVBs
(Odorizzi et al., 2003). In yeast, Bro1 recruits the deubiquitinating enzyme Doa4 to the late endosome, which is essential for
cargo deubiquitination and sorting at the MVB. However, in
mammalian cells, ALIX does not appear to function in lysosomal sorting of ubiquitinated cargo, as depletion of ALIX by
siRNA failed to affect degradation of EGFR (Cabezas et al.,
2005), a receptor that requires direct ubiquitination and ESCRTs
for degradation. We found that the association of ALIX with activated PAR1 coincided with PAR1 sorting to ILVs at the MVB.
Moreover, degradation of endogenous and ectopically expressed
PAR1 was significantly impaired in ALIX-deficient cells and
was restored by expression of an siRNA-resistant ALIX WT
variant, indicating that ALIX function is specific for this pathway. ALIX also mediated degradation of ubiquitination-deficient
PAR1, but not the related PAR2, which requires ubiquitination
for lysosomal sorting. In addition, ALIX is required for activated
PAR1 recruitment of CHMP4 subunits, the critical components
of ESCRT-III, and the ALIX Bro domain important for CHMP4
interaction is necessary for the rescue of agonist-promoted PAR1
degradation in cells deficient in endogenous ALIX expression.
Thus, ALIX has the capacity to mediate cargo sorting at the
MVB in mammalian cells through a pathway that requires
ESCRT-III recruitment. ALIX-mediated MVB sorting of PAR1
also appears to be distinctly regulated, as PAR1 does not accumulate at MVBs when ILV sorting is blocked, compared with
ubiquitinated cargo that use canonical ESCRT components. The
mechanistic basis for this observation is not known but may involve trafficking of PAR1 from the MVB to a different compartment and/or recycling back to the cell surface.
This study is the first to demonstrate ALIX-mediated
MVB/lysosomal sorting of a mammalian cell host protein via a
YPXnL motif. The ALIX central V domain has been shown to
415
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Materials and methods
Antibodies and reagents
PAR1 peptide agonists (SFLLRN and TFLLRNPNDK) and PAR2 peptide agonist (SLIGKV) were synthesized and puriﬁed by reverse-phase high-pressure
liquid chromatography at the Tufts University Core Facility. Polyclonal
anti-FLAG and -HA antibodies were obtained from Rockland Immunochemicals. Anti-LAMP1 and -CD63 antibodies were obtained from the
Developmental Studies Hybridoma Bank. Anti-EEA1 antibody was obtained from BD. Monoclonal anti-PAR1 WEDE antibody was purchased
from Beckman Coulter. Polyclonal CHMP4A and CHMP4B antibodies as
well as monoclonal anti-ALIX (3A9) and anti-Vps4 antibodies were obtained from Santa Cruz Biotechnology, Inc. The monoclonal anti-HA and -GFP
antibodies were purchased from Covance. The M2 anti-FLAG and -actin antibodies were obtained from Sigma-Aldrich. The HA antibody conjugated
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to HRP was purchased from Roche. HRP-conjugated goat–anti rabbit and
goat–anti mouse antibodies were purchased from Bio-Rad Laboratories.
Alexa Fluor 488, 594, and 647 secondary antibodies were purchased
from Invitrogen.
Plasmids and cell lines
The full-length human N-terminal FLAG-tagged PAR1 WT, FLAG-PAR1 0K
mutant cDNAs cloned into the mammalian expression vector pBJ, and fulllength FLAG-tagged PAR2 cloned into pBJ vector were previously described
(Trejo et al., 2000; Wolfe et al., 2007; Ricks and Trejo, 2009). The FLAGPAR1 Y206A mutant cloned into pBJ vector was generated by QuikChange
mutagenesis (Agilent Technologies) and conﬁrmed by dideoxy sequencing. The full-length FLAG-tagged B2AR cloned into pcDNA3.1 was provided by M. von Zastrow (University of California San Francisco, San
Francisco, CA). The GFP-tagged Vps4 WT and E228Q mutants were
cloned into pEGFP vector and provided by A. Marchese (Loyola University,
Maywood, IL). FLAG-tagged CHMP4A construct was provided by P. Hanson
(Washington University, St. Louis, MO). The cDNAs encoding HA-CHMP4B,
HA-CHMP4C, HA-ALIX WT, and HA-ALIX F676D and Bro domain mutants
were provided by J. Martin-Serrano (King’s College, London, England,
UK). GST–ALIX V, ALIX V F676D, and ALIX Bro1 constructs were provided
by W. Sundquist (University of Utah, Salt Lake City, UT). HeLa cells stably
expressing FLAG-PAR1 or FLAG-PAR2 cloned into pBJ vectors under the
control of cytomegalovirus promoter were generated by cotransfection with
a plasmid encoding a hygromycin resistance gene, selected in 250 μg/ml
hygromycin, and screened by cell surface ELISA. Cells were grown and
maintained as previously described (Trejo et al., 2000). Human endothelial EA.hy926 cells were grown and maintained as previously described
(Russo et al., 2009).
siRNA and cDNA transfections
HeLa cells or endothelial cells were transfected with 100 nM siRNA using
either Lipofectamine 2000 (Invitrogen) or Oligofectamine (Invitrogen),
respectively, and examined after 48 h. The CHMP4A, CHMP4B, CHMP4C,
Vps4A, Vps4B, and ALIX siRNAs were purchased as SMARTpools from
Thermo Fisher Scientiﬁc. The single CHMP4B siRNAs used were 1 (5-AGAAGAGUUUGACGAGGAU-3) and 2 (5-CGGAAGAGAUGUUAACGAA-3).
Nonspeciﬁc siRNA (5-GGCUACGUCCAGGAGCGCACC-3) was used
as a negative control. The ALIX knockdown rescue experiment was performed by cotransfecting HEK293 cells with ALIX-speciﬁc siRNAs (5-GUACCUCAGUCUAUAUUGA-3 and 5-UCGAGACGCUCCUGAGAUA-3;
Thermo Fisher Scientiﬁc) together with cDNAs containing HA-ALIX WT or
HA-ALIX Bro domain mutant harboring silent mutations within the siRNAtargeted region using Lipofectamine 2000 reagent.
Immuno-EM
HeLa cells stably expressing full-length FLAG-PAR1 or FLAG PAR1 0K
mutant were grown in 10-cm dishes (1.0 × 106 cells/dish) for 48 h. Cells
were washed and preincubated on ice for 1 h with anti-FLAG antibody to
label only receptors at the cell surface. Cells were washed to remove unbound antibody and treated with agonist for 20 min at 37°C, ﬁxed with
4% PFA in 0.1 M phosphate buffer, pH 7.4, overnight at room temperature, washed with 0.15 M glycine/phosphate buffer, and then embedded
in 10% gelatin/phosphate buffer infused with 2.3 M sucrose/phosphate
buffer overnight at 4°C. 1-mm3 cell blocks were mounted onto specimen
holders and snap frozen in liquid nitrogen. Ultracryomicrotomy was performed at 100°C on an ultramicrotome with an EM FCS cryoattachment
(Ultracut UCT; Leica) using a diamond knife (DiATOME US). 80–90-nm
frozen sections were picked up with a 1:1 mixture of 2.3 M sucrose and
2% methyl cellulose, as previously described (Lavoie et al., 2002), and
transferred onto Formvar and carbon-coated copper grids. Immunolabeling was performed by placing grids on 2% gelatin at 37°C for 20 min and
rinsed with 0.15 M glycine/PBS, and the sections were blocked using 1%
cold water ﬁsh skin gelatin. Previously titrated primary antibodies were diluted in 1% BSA/PBS. Incubation with primary antibodies for 1 h at room
temperature was followed by gold-conjugated goat anti–mouse IgG and
IgM (Jackson ImmunoResearch Laboratories, Inc.) or gold-conjugated goat
anti–rabbit IgG, both diluted 1/25 in 1% BSA/PBS at room temperature
for 30 min. Grids were viewed using a transmission electron microscope
(1200-EX II; JEOL) and photographed using a digital camera (Gatan, Inc)
at the University of California San Diego Electron Microscopy Facility.
PAR degradation assay
HeLa cells stably expressing FLAG-PAR1, FLAG-PAR1 0K, or FLAG-PAR2
were plated in 12-well dishes (1.5 × 105 cells/well) and grown overnight
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bind to YPXnL motifs of retroviral Gag proteins (Fisher et al.,
2007; Zhai et al., 2008). We found that ALIX directly interacts
with a highly conserved YPX3L motif within the PAR1’s intracellular loop via its V domain to facilitate MVB/lysosomal degradation. Previous studies showed that the HIV-1 and EIAV
viruses recruit the ESCRT machinery through interaction with
ALIX (Strack et al., 2003; Zhai et al., 2008) The HIV-1 structural Gag protein harbors a tetrapeptide motif that binds to
Tsg101 (Garrus et al., 2001; Martin-Serrano et al., 2001) and a
YPXnL motif that interacts with the V domain of ALIX (Strack
et al., 2003; Fisher et al., 2007) to mediate ESCRT-III recruitment. In contrast, EIAV Gag proteins only possess an ALIXbinding YPXnL motif that is critical for ESCRT-III recruitment
(Martin-Serrano et al., 2003) and viral budding (Tanzi et al.,
2003). Similar to HIV-1 and EIAV (Strack et al., 2003), mutation of the critical tyrosine within the YPX3L motif of PAR1
disrupted interaction with ALIX and impaired PAR1 MVB/
lysosomal degradation. In vitro binding assays confirmed that the
V domain of ALIX binds directly to the YPX3L motif of PAR1.
Thus, ALIX directly interacts with PAR1 and mediates MVB/
lysosomal sorting via an ESCRT-III–dependent pathway.
In summary, this study provides the first molecular insight
into a mechanism by which a signaling receptor can sort to
ILVs of MVBs independent of ubiquitination and ubiquitinbinding ESCRTs. Unlike most ubiquitinated cargo, we show
that PAR1 sorts to ILVs of MVBs through a distinct ubiquitinindependent pathway that requires ALIX and ESCRT-III function but not the canonical ubiquitin-binding ESCRT components.
These findings unveil a new mechanism that enriches the diversity of MVB sorting pathways for signaling receptors. This
work also suggests that ubiquitination of mammalian GPCRs is
likely to have additional functions besides mediating receptor
sorting at the MVB. ALIX has also been shown to bind to the
cytoplasmic tail domains of the transferrin receptor (Géminard
et al., 2004), the GPCR vasopressin V2R (Yi et al., 2007), and
D1-like and D3 dopamine GPCRs (Zhan et al., 2008) and appears to regulate various aspects of receptor trafficking. However, these cargo lack the ALIX-binding YPXnL motif, and,
thus, mechanistically how ALIX functions in these pathways is
not known. Remarkably, we discovered seven other mammalian GPCRs that contained conserved YPXnL motifs within
their second intracellular loop, raising the intriguing possibility
that ALIX mediates MVB/lysosomal sorting of a subset of
GPCRs in mammalian cells.
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at 37°C and transfected with either siRNAs or cDNA plasmids. After 48 h,
cells were washed and treated with or without 100 μM SFLLRN (PAR1speciﬁc agonist) or 100 μM SLIGKV (PAR2-speciﬁc agonist) for various
times at 37°C. Cells were placed on ice, washed with PBS, and lysed in
Triton X-100 lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM
EDTA, 50 mM NaF, 10 mM NaPP, and 1% Triton X-100) supplemented
with protease inhibitors. Cell lysates were collected and sonicated for 10 s
at 10% amplitude (model 450 soniﬁer; Branson), and protein concentrations were determined by bicinchoninic acid (BCA) assay (Thermo Fisher
Scientiﬁc). Equivalent amounts of lysates were used for analysis by immunoblotting. Endothelial cells were plated in 6-cm dishes (3.0 × 106 cells/
plate), grown for 2 d, stimulated with 100 μM TFLLRNPNDK (PAR1-speciﬁc
agonist) for various times at 37°C, and lysed with radioimmunoprecipitation assay lysis buffer (5 mM EDTA, 50 mM Tris-HCl, 150 mM NaCl,
0.5% [wt/vol] Na-deoxycholate, 1% [volume/volume] NP-40, and 0.1%
[wt/vol] SDS) supplemented with protease inhibitors, and equivalent
amounts of lysates were immunoprecipitated using the anti-PAR1 WEDE
antibody. PAR1 degradation was assessed as previously described (Russo
et al., 2009).

Immunoﬂuorescence confocal microscopy
HeLa cells stably expressing FLAG-PAR1 or FLAG-PAR2 were plated on
coverslips in 12-well dishes and grown overnight. Cells were washed, stimulated with agonists, 100 μM SFLLRN (PAR1 speciﬁc), or 100 μM SLIGKV
(PAR2 speciﬁc) for various times at 37°C, ﬁxed in 4% PFA, permeabilized
in 100% methanol, and processed for microscopy, as previously described
(Trejo et al., 2000). Cells were then immunostained with an anti-FLAG
polyclonal rabbit antibody to detect either PAR1 or PAR2 followed by
monoclonal anti-EEA1, -LAMP1, or -CD63 antibodies and then incubated
with species-speciﬁc secondary antibodies conjugated to Alexa Fluors and
imaged by confocal microscopy. To speciﬁcally track activated PAR1 or
PAR2 from the cell surface, cells were prelabeled with anti-FLAG antibody
for 1 h at 4°C to ensure only surface FLAG-PAR1 or FLAG-PAR2–bound antibody, stimulated with agonist for various times at 37°C, and then processed for microscopy. Fixed cells were mounted in FluorSave reagent
(EMD). The ﬂuorochromes used were Alexa Fluor 488, 594, and 647 and
GFP. Images were acquired with a disk-spinning unit confocal system
(Olympus) conﬁgured with a microscope (IX81; Olympus) ﬁtted with a
PlanApo 60× oil objective (1.4 NA; Olympus) and a digital camera (ORCAER; Hamamatsu Photonics). Fluorescent images of 0.28-μm-thick X–Y
sections were acquired at room temperature using SlideBook software (version 4.2; Intelligent Imaging Innovations, Inc.). Pearson’s correlation coefﬁcients for quantifying colocalization of PAR1 WT and mutants with either
EEA1 or LAMP1 were calculated for six independent cells from multiple experiments using SlideBook software (version 4.2).
Protein sequence alignment
The following protein sequences were acquired from the National Center
for Biotechnology Information protein database: Rattus norvegicus (available from GenBank under accession no. AAA42274.1), Xenopus laevis
(GenBank accession no. AAA18498.1), Mus musculus (GenBank accession
no. AAA40438.1), Papio hamadryas (GenBank accession no. AAB84191.1),
Cricetulus longicaudatus (GenBank accession no. AAA86747.1), Bos taurus
(NCBI Protein database accession no. NP_001096567.1), Equus caballus
(NCBI Protein database accession no. XP_001504007.2), Taeniopygia

In vitro binding assay
A biotinylated PAR1 ICL2 peptide representing the second intracellular
loop sequence LAVVYPMQSLSWRTLG (the segment in italics denotes the
YPXL motif within the peptide fragment, which is required for binding to
ALIX in the context of full-length PAR1) was synthesized and puriﬁed by the
Tufts University Core Facility. Biotinylated PAR1 ICL2 peptide was immobilized on streptavidin beads (Sigma-Aldrich). GST vector, GST–ALIX V,
GST–ALIX V F676D, and GST-ALIX Bro1 cDNA plasmids were transformed
into BL21 (DE3) Escherichia coli cells (Agilent Technologies). E. coli were
grown in ZYP-5052 media (1% tryptone, 0.5% yeast extract, 0.025 M
(NH4)2SO4, 0.05 M KH2PO4, 0.05 M Na2HPO4, 0.5% glycerol, 0.05%
glucose, and 0.2% A-lactose) and lysed, and GST fusion proteins were puriﬁed on GST resin (EMD). GST fusion proteins were eluted, and protein
concentrations were determined using BCA assay and GST fusion proteins
(10 μg) and then incubated with immobilized biotinylated PAR1 ICL2 peptide for 1 h at 4°C. After washing, samples were eluted in 2× sample buffer resolved by SDS-PAGE and analyzed by immunoblotting to detect
GST–ALIX association. The input, 25%, was run on an SDS-PAGE gel and
stained with Coomassie to visualize proteins.
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Coimmunoprecipitation assay
HeLa cells stably expressing FLAG-PAR1 were grown in six-well plates (4.0 ×
105 cells/well) overnight and transiently transfected with either HA-CHMP4
or HA-ALIX. Alternatively, HeLa cells plated in six-well dishes were transiently
cotransfected with PAR1 WT or Y206A mutant together with HA-ALIX. After
48 h, cells were treated with 100 μM SFLLRN (PAR1-speciﬁc agonist) for varying times at 37°C, washed, and lysed with 0.5% NP-40 lysis buffer containing 20 mM Tris-HCl, pH 7.4, and 150 mM NaCl. Cell lysates were sonicated
and cleared by centrifugation, and equivalent amounts of lysates determined
by BCA assay were precleared with protein A Sepharose CL-4B for 1 h at
4°C. Precleared lysates were then immunoprecipitated with M2 anti-FLAG
antibody or IgG overnight at 4°C. Immunoprecipitates were washed, resuspended in 2× sample buffer, resolved by SDS-PAGE, transferred to membranes, and examined by immunoblotting. For PAR1 coimmunoprecipitation
of endogenous CHMP4 and ALIX, HeLa cells expressing FLAG-PAR1 WT or
FLAG-PAR1 0K mutant were grown in six-well plates (4.0 × 105 cells/well).
After 48 h, cells were treated with agonist and lysed in buffer, as previously
stated. Equivalent amounts of lysates were then immunoprecipitated with antiPAR1 or polyclonal anti-FLAG antibodies, and the coassociation of CHMP4
or ALIX in immunoprecipitates was examined by immunoblotting.

guttata (NCBI Protein database accession no. XP_002189106.1), Danio
rerio (GenBank accession no. CAM13317.1), and Homo sapiens PAR1
(GenBank accession no. AAA36743.1) and PAR2 (GenBank accession
no. AAP97012.1). Sequences were aligned using ClustalX 2.1 software
(Larkin et al., 2007).

Proteinase K protection assay
The proteinase K protection assay was performed as previously described
(Malerød et al., 2007), with minor modiﬁcations. HeLa cells were plated
in six-well culture dishes (4.0 × 105 cells/well), grown overnight at 37°C,
and treated with or without agonist. Cells were placed on ice and incubated
for 5 min with PBS, harvested, and gently permeabilized using 6.5 μg/ml digitonin. Membranes were collected by centrifugation and resuspended in
buffer (100 mM K2HPO4/KH2PO4, 5 mM MgCl2, and 250 mM sucrose).
Membranes were then divided into three aliquots either left untreated,
treated with 2.5 ng/ml proteinase K, or treated with proteinase K supplemented with 0.1% Triton X-100 for 10 min at room temperature. After
treatments, samples were diluted with 100 μl of 2× SDS sample buffer containing 20 mM PMSF and analyzed by immunoblotting.
RT-PCR
The ﬁrst-strand cDNA was generated from mRNA extracted from either
HeLa using SuperScript II reverse transcription (Invitrogen) following the manufacturer’s instructions. The RT enzyme was omitted from the cDNA synthesis reaction in the control samples. The ﬁrst-strand cDNA was ampliﬁed
via PCR using primer pairs speciﬁc for CHMP4A (forward 5-GCATGAAGAAGGCCTACCAG-3 and reverse 5-AGGCAGGGTCACACTACCAC-3), CHMP4B (forward 5-CCCATGACAACATGGACATC-3
and reverse 5-AGCCCAGTTCTCCAATTCCT-3), or CHMP4C (forward
5-GAACTCCACAGCAATGAGCA-3 and reverse 5-AGTCATCACCAAAGCCAACC-3). The PCR ampliﬁcation products were resolved by
1.8% (wt/vol) agarose gel electrophoresis and visualized by ethidium
bromide staining.
Cell surface ELISA
HeLa cells were plated at 0.5 × 105 cells/well in a 24-well culture dish,
grown overnight, and transfected, as previously described. After 48 h,
cells were either left untreated or treated with 100 μM SFLLRN (PAR1-speciﬁc
agonist) for varying times at 37°C, and the amount of receptor remaining at the cell surface was determined, as previously described (Soto and
Trejo, 2010). In brief, cells were ﬁxed in 4% PFA, washed, and then incubated with polyclonal anti-FLAG antibody followed by secondary HRPconjugated goat anti–rabbit antibody. The amount of antibody bound
to the cell surface was determined by incubation with one-step 2,2’azinobis-3-ethylbenzthiazoline-6-sulfonic acid (Thermo Fisher Scientiﬁc)
substrate for 10–20 min at room temperature. An aliquot was removed,
and the absorbance at 405 nm was determined using a microplate reader
(SpectraMax Plus; Molecular Devices).
Statistics
Data were analyzed using Prism software (version 4.0; GraphPad Software). Statistical analysis was determined, as indicated, by performing
either Student’s t test or two-way analysis of variance.
Online supplemental material
Fig. S1 shows the localization of PAR1 WT and 0K mutant at steady state
and after stimulation with agonist for 60 min, relative to EEA1-positive
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early endosomes, and shows localization of surface-labeled PAR1 WT and
0K mutant relative to LAMP1 at 0 min and after a 20-min incubation with
or without agonist. Fig. S2 shows PAR1 degradation in cells treated with
individual siRNAs targeting CHMP4B. Fig. S3 demonstrates that Vps4
siRNA SMARTpools inhibit agonist-induced degradation of PAR1 and PAR2.
Fig. S4 shows HA-ALIX coimmunoprecipitation with FLAG-PAR1 but not
with the unrelated FLAG–B2 adrenergic receptor or FLAG-PAR2 and demonstrates that ALIX knockdown does not impair internalization of PAR1.
Fig. S5 show that PAR1 Y206A is expressed at the cell surface and is internalized comparably with WT PAR1. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.201110031/DC1.
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